Research programme: ADP-ribose hydrolases modulators - ARase Therapeutics/ HitGen
Latest Information Update: 02 Sep 2023
At a glance
- Originator HitGen
- Class Antineoplastics; Small molecules
- Mechanism of Action Hydrolase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer